Sagent Pharmaceuticals, Inc. (SGNT) Reports Q2 EPS Loss of $0.37, Revenues Grow 205%
Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) reported Q2 EPS of ($0.37), $0.16 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $32.3 million versus the consensus estimate of $34.53 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Misses Q1 EPS by 5c
- Finish Line (FINL) Tops Q1 EPS by 1c; Comps Rise 1.5%
- SYNNEX Corp. (SNX) Tops Q2 EPS by 6c; Issues Solid Q3 Outlook
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!